Adult Attention-Deficit/Hyperactivity Disorder (ADHD) and Generalised Anxiety Disorder (GAD) are both very common mental ...

The U.S. Food and Drug Administration has approved Simtriyo (centanafadine) for the treatment of ...

A new study suggests that adult-diagnosed ADHD may not be driven by distinct environmental pathways, with executive function emerging as the clearest link to symptom severity across age-of-diagnosis ...

Add Yahoo as a preferred source to see more of our stories on Google. People with ADHD have trouble with attention, organisation, time management and self-control Attention deficit hyperactivity ...

I find it so rewarding working with patients with Adult ADHD because an accurate diagnosis and effective treatment can greatly impact a person's career, health, and quality of life. For example, the ...

"Hearst Magazines and Yahoo may earn commission or revenue on some items through these links." STRUGGLING TO CONCENTRATE, running late, or being forgetful are things most of us deal with from time to ...

New research reveals ADHD isn't one-size-fits-all — covering social media's specific role, why medication rarely 'stops ...

Once believed to be a condition that children outgrow, attention deficit hyperactivity disorder (ADHD) is now recognized as a ...

The FDA has approved Simtriyo (centanafadine) as the first norepinephrine, dopamine, serotonin reuptake inhibitor for adult and pediatric ADHD.

Centanafadine XR demonstrated efficacy in improving symptoms in adults with attention-deficit/hyperactivity disorder and comorbid anxiety.

The Food and Drug Administration (FDA) approved a new "first-in-class" medication to help manage attention deficit ...